ReviewFrontiers in endocrinology2020
Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06413043 (Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy: A Randomized Control Trial
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Adding L-Carnitine and Selenium to Methimazole in Graves' Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life.Nutrients · 2025Trial
- Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment.Frontiers in endocrinology · 2022Trial
- Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression.The Journal of clinical endocrinology and metabolism · 2026Observational
- Efficacy of Selenium Supplementation in Graves' Orbitopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.Journal of clinical medicine · 2026Review
- Selenium Supplementation in Graves' Orbitopathy: Effects on Blood Concentrations and Clinical Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Recent Progress in Selenium Nanomedicines for Ocular Diseases.International journal of nanomedicine · 2026Review
- Review
- Evaluation of selenoproteins and proinflammatory cytokines in L-thyroxine-induced hyperthyroid rats: effects of selenium supplementation.Archives of endocrinology and metabolism · 2025Article
- Article
- Selenium: Could It Be the Game-Changer for Ocular Surface and Anterior Chamber in Graves' Disease?Beyoglu eye journal · 2025Article
- GPX1-driven selenium nanoplatform reprograms MAMs-mediated organelle crosstalk to reverse inflammatory adipose expansion in thyroid eye disease.Theranostics · 2025Article
- Subclinical Ocular Motility Dysfunction and Extraocular Muscle Changes in Inactive Graves' Orbitopathy.Journal of personalized medicine · 2024Article
- One Incremental Stride for Doxycycline, One Substantial Advancement for Thyroid Eye Disease.Diagnostics (Basel, Switzerland) · 2024Article
- The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.International journal of molecular sciences · 2024Review
- Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.Hormones (Athens, Greece) · 2024Review
- A follow-up study on factors affecting the recovery of patients with hypothyroidism in different selenium environments.BMC endocrine disorders · 2024Article
- Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?Antioxidants (Basel, Switzerland) · 2023Review
- Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.International ophthalmology · 2023Review
- Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.Thyroid : official journal of the American Thyroid Association · 2022Article
- Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.European thyroid journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the role of oxidative stress in the pathogenesis of Graves' hyperthyroidism (GH) and Graves' Orbitopathy (GO), a therapy with the antioxidant agent selenium has been proposed and a number of studies have been performed, both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.